Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 9/20 | 0.63 |
| ▸ | GUCY1B2 | O75343 | 2/20 | 0.36 |
| ▸ | GUCY1A2 | P33402 | 2/20 | 0.36 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.36 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.32 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437756 | 1.00 | IGF1R (0.63) | IGF1RGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL1270154 | 0.93 | IGF1R (0.73) | IGF1RKDM5AJAK2KDM4EPOLB | |
| SCHEMBL1270424 | 0.91 | IGF1R (0.61) | IGF1RKDM5AJAK2 | |
| SCHEMBL1270637 | 0.91 | IGF1R (0.51) | IGF1RGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL1270428 | 0.88 | IGF1R (0.57) | IGF1RGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL12923859 | 0.84 | IGF1R (0.87) | IGF1RJAK2 | |
| SCHEMBL12337594 | 0.84 | IGF1R (0.87) | IGF1RJAK2 | |
| SCHEMBL1269810 | 0.84 | IGF1R (0.50) | IGF1RKDM5AJAK2 | |
| SCHEMBL1269983 | 0.80 | IGF1R (0.47) | IGF1RJAK2POLB | |
| SCHEMBL1270284 | 0.79 | IGF1R (0.48) | IGF1RGUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041138-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8592579-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | disclosed |
| US-8263765-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| US-7879855-B2 | administering (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide, for the treatment of cancers of the colon, lung, ovary, and pancreas; anticarcinogenic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-24 | — | — | US | disclosed |
| US-7534792-B2 | e.g. 1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-methylpyrrolidine-2-carboxamide; tyrosine kinase inhibitor; anticarcinogenic, antiproliferative agent, neurodegenerative diseases; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885GUCY1B2 2893/4885GUCY1A2 1843/4885 |
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885GUCY1B2 2893/4885GUCY1A2 1843/4885 |
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885GUCY1B2 2893/4885GUCY1A2 1843/4885 |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885GUCY1B2 2893/4885GUCY1A2 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.